PE20060745A1 - COMBINACIONES FARMACEUTICAS QUE COMPRENDEN ((S)-N-[2-(1,6,7,8-TETRAHIDRO-2H-INDENO[5,4-b]FURAN-8-IL)ETIL]PROPIONAMIDA - Google Patents

COMBINACIONES FARMACEUTICAS QUE COMPRENDEN ((S)-N-[2-(1,6,7,8-TETRAHIDRO-2H-INDENO[5,4-b]FURAN-8-IL)ETIL]PROPIONAMIDA

Info

Publication number
PE20060745A1
PE20060745A1 PE2005001435A PE2005001435A PE20060745A1 PE 20060745 A1 PE20060745 A1 PE 20060745A1 PE 2005001435 A PE2005001435 A PE 2005001435A PE 2005001435 A PE2005001435 A PE 2005001435A PE 20060745 A1 PE20060745 A1 PE 20060745A1
Authority
PE
Peru
Prior art keywords
sleep
propionamide
indene
furan
tetrahydro
Prior art date
Application number
PE2005001435A
Other languages
English (en)
Inventor
Keisuke Hirai
Masaomi Miyamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36587809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060745(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20060745A1 publication Critical patent/PE20060745A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

REFERIDA A UNA COMBINACION FARMACEUTICA DE: A) UN ANTAGONISTA DE MELATONINA TAL COMO ((S)-N-[2-(1,6,7,8-TETRAHIDRO-2H-INDENO[5,4-b]FURAN-8-IL)ETIL]PROPIONAMIDA Y B) UN COMPUESTO FARMACEUTICO SELECCIONADO DE COMPUESTOS ANTAGONISTAS DE LOS RECEPTORES 5-HT2A, 5-HT2C, 5-HT2A/2C, INHIBIDORES DE LA RECAPTACION DE SEROTONINA, MODULADORES DE GABA E INHIBIDORES DE CAPTACION DE GABA, TALES COMO M-100907, RITANSERIN, GABAPENTIN, TIAGABIN, TRAZODONE, ORG-500081 Y EPLIVANSERIN. DICHA COMBINACION ES UTIL PARA INDUCIR EL SUENO NATURAL, REDUCIR LA LATENCIA DEL SUENO, AUMENTAR LA PROFUNDIDAD DEL SUENO, MANTENER EL SUENO Y PROPORCIONAR PERIODOS DE SUENO ADECUADOS
PE2005001435A 2004-12-13 2005-12-12 COMBINACIONES FARMACEUTICAS QUE COMPRENDEN ((S)-N-[2-(1,6,7,8-TETRAHIDRO-2H-INDENO[5,4-b]FURAN-8-IL)ETIL]PROPIONAMIDA PE20060745A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004359487 2004-12-13

Publications (1)

Publication Number Publication Date
PE20060745A1 true PE20060745A1 (es) 2006-09-05

Family

ID=36587809

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001435A PE20060745A1 (es) 2004-12-13 2005-12-12 COMBINACIONES FARMACEUTICAS QUE COMPRENDEN ((S)-N-[2-(1,6,7,8-TETRAHIDRO-2H-INDENO[5,4-b]FURAN-8-IL)ETIL]PROPIONAMIDA

Country Status (17)

Country Link
US (1) US20080242682A1 (es)
EP (1) EP1832286A4 (es)
JP (1) JPWO2006064754A1 (es)
KR (1) KR20070085973A (es)
CN (1) CN101076328A (es)
AR (1) AR052152A1 (es)
AU (1) AU2005314935A1 (es)
BR (1) BRPI0519016A2 (es)
CA (1) CA2590838A1 (es)
IL (1) IL183520A0 (es)
MA (1) MA29085B1 (es)
MX (1) MX2007006825A (es)
NO (1) NO20073590L (es)
PE (1) PE20060745A1 (es)
RU (1) RU2007126638A (es)
TW (1) TW200626137A (es)
WO (1) WO2006064754A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080034475A (ko) * 2005-08-19 2008-04-21 아벤티스 파마슈티칼스 인크. 수면제 및ｒ(＋)-알파-(2,3-디메톡시-페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올의 복합물 및 이의 치료학적 용도
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
EP2236511A4 (en) 2007-12-21 2011-04-13 Alla Chem Llc LIGANDS OF ALPHA ADRENOCEPTORS AND OF DOPAMINE, HISTAMIN, IMIDAZOLIN AND SEROTONIN RECEPTORS AND THEIR APPLICATION THEREOF
EP2266554A1 (en) * 2009-05-26 2010-12-29 Sanofi-Aventis Method of treating sleep disorders using eplivanserin
EP2365805A1 (en) * 2008-11-13 2011-09-21 Sanofi Method of treating sleep disorders using eplivanserin
EP2255726A1 (en) * 2009-05-26 2010-12-01 Sanofi-Aventis Spectral profile of SWS enhancing drugs
EP2269600A1 (en) * 2009-07-02 2011-01-05 Sanofi-Aventis Treatment of sleep disorders using eplivanserin in COPD patients
KR20130002292A (ko) * 2011-06-28 2013-01-07 주식회사 비보존 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
WO2021205648A1 (ja) * 2020-04-10 2021-10-14 国立大学法人東海国立大学機構 精神障害患者の客観的睡眠評価方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
PL188093B1 (pl) * 1996-03-08 2004-12-31 Takeda Chemical Industries Ltd Związek trójpierścieniowy, sposób jego wytwarzania i zastosowanie, kompozycja farmaceutyczna oraz związki pośrednie
JP4081161B2 (ja) * 1997-09-05 2008-04-23 武田薬品工業株式会社 光学活性化合物の製造法
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
ATE247967T1 (de) * 1998-06-09 2003-09-15 Takeda Chemical Industries Ltd Pharmazeutische kombination mit einem trizyclischen komponent und mindestens einem aus zolpidem, zopiclone und brotizolam, zur behandlung von schlafstörungen
US20030165566A1 (en) * 2002-01-10 2003-09-04 O'toole Edel Sedative non-benzodiazepine formulations
PL371407A1 (en) * 2002-01-10 2005-06-13 Biovail Laboratories Inc. Sedative non-benzodiazepine formulations
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
CA2551637A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.

Also Published As

Publication number Publication date
RU2007126638A (ru) 2009-01-20
CA2590838A1 (en) 2006-06-22
IL183520A0 (en) 2007-09-20
MA29085B1 (fr) 2007-12-03
US20080242682A1 (en) 2008-10-02
JPWO2006064754A1 (ja) 2008-06-12
MX2007006825A (es) 2007-07-25
WO2006064754A1 (ja) 2006-06-22
AU2005314935A1 (en) 2006-06-22
KR20070085973A (ko) 2007-08-27
EP1832286A4 (en) 2009-11-18
NO20073590L (no) 2007-09-03
AR052152A1 (es) 2007-03-07
BRPI0519016A2 (pt) 2008-12-23
CN101076328A (zh) 2007-11-21
TW200626137A (en) 2006-08-01
EP1832286A1 (en) 2007-09-12

Similar Documents

Publication Publication Date Title
PE20060745A1 (es) COMBINACIONES FARMACEUTICAS QUE COMPRENDEN ((S)-N-[2-(1,6,7,8-TETRAHIDRO-2H-INDENO[5,4-b]FURAN-8-IL)ETIL]PROPIONAMIDA
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
PE20160548A1 (es) Sulfonamidas como moduladores de canales de sodio
UY31063A1 (es) Derivados de n-[6-amino-5-aril-piridin -2-il]-carboxamida, composiciones conteniéndolos, procedimientos de preparación, itermedios utilizados en la preparación y aplicaciones.
CO6300939A2 (es) Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
PE20140604A1 (es) Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
ECSP066520A (es) Derivados de dihidrobenzofuranilo alcanamina y métodos para su uso
AR059754A1 (es) Inhibidores de gsk3 para el tratamiento de osteoporosis
CU20100238A7 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
EA200801001A1 (ru) Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
CR6616A (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
CO6270328A2 (es) Derivados de pirrolo [2,3] pirimidina como inhibidores de proteinas quinasas b
ECSP099706A (es) Nuevos derivados de n-(8-heteroariltetrahidronaftalen-2yl) y n-(5-heteroarilcroman-3-il) carboxamida para el tratamiento del dolor
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
CO6260069A2 (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa
AR090712A1 (es) Agentes para tratar trastornos que implican la modulacion de receptores de rianodina
AR050260A1 (es) Derivados de diarilmetilpiperazinas, su preparacion y su utilizacion
AR093042A1 (es) Derivados de etinilo
UY33506A (es) Nuevas formas cristalinas de N-[2-[[(2,3-difluorofenil)metil]tio]-6-{[(1R, 2S)-2,3-dihidroxi-1-metilpropil]oxi}-4-pirimidinil]-1-azetidinsulfonamida

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed